The present invention relates to substituted 1,2-ethylenediamines of general formula (I) ##STR00001## wherein the groups R.sup.1 to R.sup.15, A, B, L, i as well as X.sup.1--X.sup.4 are defined as in the specification and claims and the use thereof for the treatment of Alzheimer's disease (AD) and similar diseases.